OBJECTIVE: The purpose of this study was to investigate the effect of acute and chronic whole-body vibration exercise on serum insulin-like growth factor-1 (IGF-1) levels in women with fibromyalgia. METHODS: A randomized controlled two-factor mixed experimental design was used. Twenty-four women with fibromyalgia (age +/- standard error of the mean, 54.95 +/- 2.03) were randomized into the vibration group or the control group. The vibration group underwent a protocol of static and dynamic tasks with whole-body vibration exercise twice a week for a total of six weeks, whereas the control group performed the same protocol without vibratory stimulus. Both groups continued their usual pharmacological treatment. Serum IGF-1 levels were determined using enzyme-linked immunosorbent assay (ELISA). To test the effects of long-term whole-body vibration exercise, serum IGF-1 measurements were taken at baseline and at weeks 1, 3, and 6 of the intervention. To test the short-term effects, at week 1, serum IGF-1 measurements were taken before and immediately following a session of whole-body vibration exercise. RESULTS:Treatment adherence was 93% in the vibration group and 92% in the control group. None of the subjects dropped out of the study. There was an absence of change in IGF-1 at week 1 and week 6 of whole-body vibration exercise. CONCLUSION: Results show no change in serum IGF-1 levels in women with fibromyalgia undergoing whole-body vibration exercise. Although high-intensity exercise and whole-body vibration exercise have been shown to increase serum IGF-1 in healthy individuals, the effectiveness of whole-body vibration exercise as a strategy to produce improvements in serum IGF-1 levels in women with fibromyalgia could not be demonstrated.
RCT Entities:
OBJECTIVE: The purpose of this study was to investigate the effect of acute and chronic whole-body vibration exercise on serum insulin-like growth factor-1 (IGF-1) levels in women with fibromyalgia. METHODS: A randomized controlled two-factor mixed experimental design was used. Twenty-four women with fibromyalgia (age +/- standard error of the mean, 54.95 +/- 2.03) were randomized into the vibration group or the control group. The vibration group underwent a protocol of static and dynamic tasks with whole-body vibration exercise twice a week for a total of six weeks, whereas the control group performed the same protocol without vibratory stimulus. Both groups continued their usual pharmacological treatment. Serum IGF-1 levels were determined using enzyme-linked immunosorbent assay (ELISA). To test the effects of long-term whole-body vibration exercise, serum IGF-1 measurements were taken at baseline and at weeks 1, 3, and 6 of the intervention. To test the short-term effects, at week 1, serum IGF-1 measurements were taken before and immediately following a session of whole-body vibration exercise. RESULTS: Treatment adherence was 93% in the vibration group and 92% in the control group. None of the subjects dropped out of the study. There was an absence of change in IGF-1 at week 1 and week 6 of whole-body vibration exercise. CONCLUSION: Results show no change in serum IGF-1 levels in women with fibromyalgia undergoing whole-body vibration exercise. Although high-intensity exercise and whole-body vibration exercise have been shown to increase serum IGF-1 in healthy individuals, the effectiveness of whole-body vibration exercise as a strategy to produce improvements in serum IGF-1 levels in women with fibromyalgia could not be demonstrated.
Authors: Daniel Collado-Mateo; Jose C Adsuar; Pedro R Olivares; Borja Del Pozo-Cruz; Jose A Parraca; Jesus Del Pozo-Cruz; Narcis Gusi Journal: Evid Based Complement Alternat Med Date: 2015-08-17 Impact factor: 2.629
Authors: Donato S Braz Júnior; Arméle Dornelas de Andrade; Andrei S Teixeira; Cléssyo A Cavalcanti; André B Morais; Patrícia Em Marinho Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-01-12
Authors: Julia Bidonde; Angela J Busch; Candice L Schachter; Tom J Overend; Soo Y Kim; Suelen M Góes; Catherine Boden; Heather Ja Foulds Journal: Cochrane Database Syst Rev Date: 2017-06-21